AOD-9604
AOD-9604 is a weight management peptide used in evidence-based, physician-supervised protocols. Use for stubborn fat loss, especially visceral and subcutaneous fat resistant to diet.
What is AOD-9604?
C-terminal fragment (176-191) of human GH. Stimulates lipolysis via beta-3 adrenergic receptors and inhibits lipogenesis without IGF-1 elevation or glucose dysregulation. No anabolic effects.
Uses & clinical decision logic
Use for stubborn fat loss, especially visceral and subcutaneous fat resistant to diet. Must administer fasted (pre-bed or upon waking) for maximum lipolytic effect. Split AM/PM doses for sustained effect.
AOD-9604 dosage & administration
| Vial size | BAC water | Dosing range | Units / dose | Frequency | Route |
|---|---|---|---|---|---|
| 5mg | 5mL | 500mcg-1mg | 50-100 units | 5 days on / 2 off | SubQ |
| 10mg | 10mL | 500mcg-1mg | 50-100 units | 5 days on / 2 off | SubQ |
Safety & contraindications
No IGF-1 or insulin interaction — safe for diabetics.
Stacking & combinations
Pairs with HGH Frag 176-191 (same mechanism, different vial concentration). Combine with GH peptides (CJC/Ipa) for GH + lipolysis synergy. Compatible with GLP-1 agents.
Frequently asked questions
What is AOD-9604 used for?
Use for stubborn fat loss, especially visceral and subcutaneous fat resistant to diet. Must administer fasted (pre-bed or upon waking) for maximum lipolytic effect. Split AM/PM doses for sustained effect.
What is the typical AOD-9604 dosage?
Common dosing ranges from 500mcg-1mg (5 days on / 2 off, SubQ). Exact dosing is individualized and set by a licensed physician.
How is AOD-9604 administered?
AOD-9604 is typically administered via SubQ.
What are the contraindications for AOD-9604?
No IGF-1 or insulin interaction — safe for diabetics.
Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.
Build your protocol →This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.